HK1217173A1 - 含有肉毒杆菌神经毒素的药物组合物及其应用 - Google Patents

含有肉毒杆菌神经毒素的药物组合物及其应用 Download PDF

Info

Publication number
HK1217173A1
HK1217173A1 HK16105183.8A HK16105183A HK1217173A1 HK 1217173 A1 HK1217173 A1 HK 1217173A1 HK 16105183 A HK16105183 A HK 16105183A HK 1217173 A1 HK1217173 A1 HK 1217173A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
botulinum neurotoxin
botulinum toxin
mucopolysaccharide
composition containing
Prior art date
Application number
HK16105183.8A
Other languages
English (en)
Chinese (zh)
Inventor
Evgeny POKUSHALOV
Vladislav FOMENKO
Nariman SALAKHUDINOV
Original Assignee
Bosti Trading Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bosti Trading Ltd. filed Critical Bosti Trading Ltd.
Publication of HK1217173A1 publication Critical patent/HK1217173A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK16105183.8A 2013-05-15 2014-05-14 含有肉毒杆菌神经毒素的药物组合物及其应用 HK1217173A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2013122509 2013-05-15
RU2013122509/15A RU2535115C1 (ru) 2013-05-15 2013-05-15 Фармацевтический состав, содержащий нейротоксин ботулина
PCT/IB2014/061417 WO2014184746A1 (en) 2013-05-15 2014-05-14 Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof

Publications (1)

Publication Number Publication Date
HK1217173A1 true HK1217173A1 (zh) 2016-12-30

Family

ID=50841919

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105183.8A HK1217173A1 (zh) 2013-05-15 2014-05-14 含有肉毒杆菌神经毒素的药物组合物及其应用

Country Status (10)

Country Link
US (1) US10258673B2 (https=)
EP (2) EP3750525A1 (https=)
JP (1) JP6440691B2 (https=)
CN (1) CN105209014B (https=)
CA (1) CA2911046C (https=)
DK (1) DK2996674T3 (https=)
ES (1) ES2829614T3 (https=)
HK (1) HK1217173A1 (https=)
RU (1) RU2535115C1 (https=)
WO (1) WO2014184746A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015253045B2 (en) * 2014-04-30 2020-07-16 Allergan, Inc. Formulations of biologics for intravesical instillation
DK3174523T3 (da) * 2014-07-31 2020-09-28 Allergan Inc Formuleringer af biologiske stoffer til intravesikal instillation
RU2577296C1 (ru) * 2014-12-24 2016-03-10 Евгения Николаевна Анисимова Способ выбора эффективного и безопасного местного обезболивания у пациентов с артериальной гипертензией на амбулаторном стоматологическом приеме
RU2651044C2 (ru) * 2016-08-22 2018-04-18 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. ак. Е.Н. Мешалкина" Минздрава России) Способ лечения желудочковых нарушений ритма сердца (варианты)
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
JP2020525416A (ja) * 2017-06-29 2020-08-27 アドヴァイテ エルエルシー． 眼表面障害の治療及び診断
WO2019241296A1 (en) * 2018-06-13 2019-12-19 Dermata Therapeutics, Llc Compositions for the treatment of skin conditions
AU2019337656A1 (en) * 2018-09-13 2021-05-06 Allergan, Inc. Methods for treatment of masseter muscle hypertrophy
KR102520631B1 (ko) 2019-10-18 2023-04-12 펜랜드 파운데이션 치료에 사용하기 위한 보톨리늄 독소
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
WO2021231666A1 (en) 2020-05-15 2021-11-18 Penland Foundation Treatment of asthma using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
US10960060B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
US11090371B1 (en) 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
US11925677B2 (en) 2021-07-12 2024-03-12 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
WO2023287729A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of acute and chronic kidney disease
US20250295741A1 (en) * 2022-11-07 2025-09-25 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2884358A (en) 1957-04-22 1959-04-28 Southern California Gland Co Process for preparing crude heparin
JPH06192296A (ja) * 1992-10-28 1994-07-12 Chiba Pref Gov 治療用医薬品としての結晶ａ型ボツリヌス毒素の製造法。
US6967088B1 (en) 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20120238504A1 (en) * 1998-09-11 2012-09-20 Solstice Neurosciences, Llc Stable Formulations of Botulinum Toxin in Hydrogels
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US8073538B2 (en) * 2003-11-13 2011-12-06 Cardio Polymers, Inc. Treatment of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart
WO2005049111A2 (en) * 2003-11-13 2005-06-02 Symphony Medical, Inc. Control of cardiac arrhythmias by modification of neuronal conduction within fat pads of the heart
US20060228404A1 (en) * 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
JP2005306746A (ja) * 2004-04-19 2005-11-04 Jiyugaoka Clinic 顔面用シワ治療剤
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
GB2419817A (en) * 2004-10-29 2006-05-10 Ipsen Ltd Treatment of cardiac fibrillation disorders
WO2007019554A2 (en) * 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
AU2007249682B2 (en) * 2006-05-15 2013-05-16 Cardiopolymers, Inc. Post-operative control of cardiac arrhythmia by modification of neuronal signaling
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US8821928B2 (en) * 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
JP4999008B2 (ja) 2008-07-15 2012-08-15 楽天株式会社 情報送信装置、情報送信方法、情報送信処理プログラム及び情報送信システム
AU2009332947C1 (en) 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
AU2015253045B2 (en) * 2014-04-30 2020-07-16 Allergan, Inc. Formulations of biologics for intravesical instillation

Also Published As

Publication number Publication date
ES2829614T3 (es) 2021-06-01
JP6440691B2 (ja) 2018-12-19
JP2016518442A (ja) 2016-06-23
WO2014184746A1 (en) 2014-11-20
CA2911046A1 (en) 2014-11-20
RU2535115C1 (ru) 2014-12-10
US20160114013A1 (en) 2016-04-28
CN105209014B (zh) 2018-05-25
EP3750525A1 (en) 2020-12-16
US10258673B2 (en) 2019-04-16
CN105209014A (zh) 2015-12-30
CA2911046C (en) 2021-08-31
EP2996674A1 (en) 2016-03-23
DK2996674T3 (da) 2020-10-26
EP2996674B1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
HK1217173A1 (zh) 含有肉毒杆菌神经毒素的药物组合物及其应用
ZA201900341B (en) A novel botulinum neurotoxin and its derivatives
EP3156412A4 (en) Novel cell penetrating peptide, conjugate thereof with botulinum toxin, and use thereof
EP3114217A4 (en) Caspase polypeptides having modified activity and uses thereof
EP3510049B8 (en) Acid-alpha glucosidase variants and uses thereof
EP2967081A4 (en) Modified caspase polypeptides and uses thereof
EP3845241A8 (en) Long lasting effect of new botulinum toxin formulations
EP3039131A4 (en) Enzyme composition and uses thereof
EP3275490A4 (en) Injection needle assembly, and drug injection device
SI2909307T1 (sl) Kompozicije in metode, povezane z mutantnim toksinom clostridium difficile
EP3023477A4 (en) Composition, and light-emitting element using same
EP3233111A4 (en) Pharmaceutical composition comprising plasminogen and uses thereof
EP3077413A4 (en) Polypeptides, nucleic acids and uses thereof
EP3278828A4 (en) Injection pen
EP3118287A4 (en) Grease composition and grease-filled wheel bearing
EP3307265A4 (en) Pharmaceutical combination and uses thereof
EP3068443A4 (en) Residualizing linkers and uses thereof
EP3020990A4 (en) Seal ring-equipped ball bearing
EP3439632B8 (en) Topical composition comprising tacrolimus
EP3258128A4 (en) Bearing cap having sensor unit, and rolling bearing unit
EP3170528A4 (en) Micro-needle and micro-needle assembly
EP3038743A4 (en) Tower packing element, tower packing, and packing tower and mixer comprising the same
MX362070B (es) Polioles que contienen tanino, su producción y su uso.
EP3021002A4 (en) Laminate sliding member, and sliding bearing using said laminate sliding member
EP3175845A4 (en) Pharmaceutical composition provided with abuse-prevention function